These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

253 related items for PubMed ID: 18033225

  • 1. What nephrologists need to know about gadolinium.
    Penfield JG, Reilly RF.
    Nat Clin Pract Nephrol; 2007 Dec; 3(12):654-68. PubMed ID: 18033225
    [Abstract] [Full Text] [Related]

  • 2. [Nephrogenic systemic fibrosis].
    Breitschaft A, Stahlmann R.
    Med Monatsschr Pharm; 2009 Oct; 32(10):377-82. PubMed ID: 19886227
    [Abstract] [Full Text] [Related]

  • 3. Gadolinium-associated nephrogenic systemic fibrosis: the need for nephrologists' awareness.
    Canavese C, Mereu MC, Aime S, Lazzarich E, Fenoglio R, Quaglia M, Stratta P.
    J Nephrol; 2008 Oct; 21(3):324-36. PubMed ID: 18587720
    [Abstract] [Full Text] [Related]

  • 4. [Nephrogenic systemic fibrosis after application of gadolinium-based contrast agents--a status paper].
    Heinrich M, Uder M.
    Rofo; 2007 Jun; 179(6):613-7. PubMed ID: 17497597
    [Abstract] [Full Text] [Related]

  • 5. Patient characteristics and risk factors for nephrogenic systemic fibrosis following gadolinium exposure.
    Grobner T, Prischl FC.
    Semin Dial; 2008 Jun; 21(2):135-9. PubMed ID: 18226001
    [Abstract] [Full Text] [Related]

  • 6. [Nephrogenic systemic fibrosis].
    Cavallini L, Abaterusso C, Bedogna V, Pertica N, Loschiavo C, Lupo A.
    G Ital Nefrol; 2008 Jun; 25(1):14-20. PubMed ID: 18264914
    [Abstract] [Full Text] [Related]

  • 7. Nephrogenic systemic fibrosis--implications for nephrologists.
    Saab G, Abu-Alfa A.
    Eur J Radiol; 2008 May; 66(2):208-12. PubMed ID: 18342470
    [Abstract] [Full Text] [Related]

  • 8. [Nephrogenic systemic fibrosis and gadolinium-based contrast media].
    Andréjak M, Thuillier D, Lok C, Gras-Champel V.
    Therapie; 2007 May; 62(2):169-72. PubMed ID: 17582319
    [Abstract] [Full Text] [Related]

  • 9. Risk factors for developing gadolinium-induced nephrogenic systemic fibrosis.
    Peak AS, Sheller A.
    Ann Pharmacother; 2007 Sep; 41(9):1481-5. PubMed ID: 17684032
    [Abstract] [Full Text] [Related]

  • 10. MRI gadolinium-based contrast agents. Radiologists beware!
    Goullé JP, Cattanéo A, Saussereau E, Mahieu L, Guerbet M, Lacroix C.
    Ann Pharm Fr; 2009 Sep; 67(5):335-9. PubMed ID: 19695369
    [Abstract] [Full Text] [Related]

  • 11. Extracellular Gd-CA: differences in prevalence of NSF.
    Thomsen HS, Marckmann P.
    Eur J Radiol; 2008 May; 66(2):180-3. PubMed ID: 18342468
    [Abstract] [Full Text] [Related]

  • 12. Nephrogenic systemic fibrosis: more questions and some answers.
    Morcos SK, Thomsen HS.
    Nephron Clin Pract; 2008 May; 110(1):c24-31; discussion c32. PubMed ID: 18688172
    [Abstract] [Full Text] [Related]

  • 13. Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study.
    Kallen AJ, Jhung MA, Cheng S, Hess T, Turabelidze G, Abramova L, Arduino M, Guarner J, Pollack B, Saab G, Patel PR.
    Am J Kidney Dis; 2008 Jun; 51(6):966-75. PubMed ID: 18501784
    [Abstract] [Full Text] [Related]

  • 14. Possible involvement of gadolinium chelates in the pathophysiology of nephrogenic systemic fibrosis: a critical review.
    Idée JM, Port M, Medina C, Lancelot E, Fayoux E, Ballet S, Corot C.
    Toxicology; 2008 Jun 27; 248(2-3):77-88. PubMed ID: 18440117
    [Abstract] [Full Text] [Related]

  • 15. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent.
    Rydahl C, Thomsen HS, Marckmann P.
    Invest Radiol; 2008 Feb 27; 43(2):141-4. PubMed ID: 18197066
    [Abstract] [Full Text] [Related]

  • 16. Nephrogenic system fibrosis: a radiologist's practical perspective.
    Martin DR.
    Eur J Radiol; 2008 May 27; 66(2):220-4. PubMed ID: 18321672
    [Abstract] [Full Text] [Related]

  • 17. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting.
    Broome DR.
    Eur J Radiol; 2008 May 27; 66(2):230-4. PubMed ID: 18372138
    [Abstract] [Full Text] [Related]

  • 18. The impact of NSF on the care of patients with kidney disease.
    Abu-Alfa A.
    J Am Coll Radiol; 2008 Jan 27; 5(1):45-52. PubMed ID: 18180009
    [Abstract] [Full Text] [Related]

  • 19. Gadolinium-containing MRI contrast agents: important variations on a theme for NSF.
    Kuo PH.
    J Am Coll Radiol; 2008 Jan 27; 5(1):29-35. PubMed ID: 18180006
    [Abstract] [Full Text] [Related]

  • 20. Gadolinium-induced nephrogenic systemic fibrosis in a patient with an acute and transient kidney injury.
    Kalb RE, Helm TN, Sperry H, Thakral C, Abraham JL, Kanal E.
    Br J Dermatol; 2008 Mar 27; 158(3):607-10. PubMed ID: 18076707
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.